"Most venture capital groups don't have the bandwidth to cover life sciences and nanotechnology. You can count on one hand the number of VCs who understand both."

— Spencer Farr, PhD, president/CEO of Vista Therapeutics, discussing the company's strategy to partner with other firms rather than raise venture capital, "NanobioSensors will provide real-time patient monitoring," pp. 1, 7.